Citations (65)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
James W. Hopper. (2020) Values and visions for the field of psychological trauma, from brain to re-moralization and social transformation. Journal of Trauma & Dissociation 21:3, pages 279-292.
Read now
Read now
Alexander Trope, Brian T. Anderson, Andrew R. Hooker, Giancarlo Glick, Christopher Stauffer & Joshua D. Woolley. (2019) Psychedelic-Assisted Group Therapy: A Systematic Review. Journal of Psychoactive Drugs 51:2, pages 174-188.
Read now
Read now
David E. Smith. (2019) The Role of the Journal of Psychedelic Drugs in the Evolution of Psychedelic Medicine. Journal of Psychoactive Drugs 51:2, pages 98-101.
Read now
Read now
Albert Garcia-Romeu & William A. Richards. (2018) Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions. International Review of Psychiatry 30:4, pages 291-316.
Read now
Read now
David E. Smith, Glenn E. Raswyck & Leigh Dickerson Davidson. (2014) From Hofmann to the Haight Ashbury, and into the Future: The Past and Potential of Lysergic Acid Diethlyamide. Journal of Psychoactive Drugs 46:1, pages 3-10.
Read now
Read now
Petr Winkler & Ladislav Csémy. (2014) Self-Experimentations with Psychedelics Among Mental Health Professionals: LSD in the Former Czechoslovakia. Journal of Psychoactive Drugs 46:1, pages 11-19.
Read now
Read now
Anja Loizaga-Velder & Rolf Verres. (2014) Therapeutic Effects of Ritual Ayahuasca Use in the Treatment of Substance Dependence—Qualitative Results. Journal of Psychoactive Drugs 46:1, pages 63-72.
Read now
Read now
Mitchell
B. Liester & James
I. Prickett. (2012) Hypotheses Regarding the Mechanisms of Ayahuasca in the Treatment of Addictions. Journal of Psychoactive Drugs 44:3, pages 200-208.
Read now
Read now
R. L. Carhart-Harris & D. J. Nutt. (2010) User perceptions of the benefits and harms of hallucinogenic drug use: A web-based questionnaire study. Journal of Substance Use 15:4, pages 283-300.
Read now
Read now
Robin Carhart-Harris. (2007) Waves of the Unconscious: The Neurophysiology of Dreamlike Phenomena and Its Implications for the Psychodynamic Model of the Mind. Neuropsychoanalysis 9:2, pages 183-211.
Read now
Read now
Articles from other publishers (55)
Shannon Dames, Crosbie WatlerPamela KryskowPearl AllardMichelle GagnonWes TaylorVivian W.L. Tsang. (2024) Psychedelic-Assisted Therapy Training: An Argument in Support of Firsthand Experience of Nonordinary States of Consciousness in the Development of Competence. Psychedelic Medicine.
Crossref
Crossref
Jennifer M. Mitchell & Brian T. Anderson. (2023) Psychedelic therapies reconsidered: compounds, clinical indications, and cautious optimism. Neuropsychopharmacology 49:1, pages 96-103.
Crossref
Crossref
David B. Yaden, Andrea P. Berghella, Peter S. Hendricks, Mary E. Yaden, Michael Levine, Julia S. Rohde, Sandeep Nayak, Matthew W. Johnson & Albert Garcia-Romeu. (2024) IUPHAR-review: The integration of classic psychedelics into current substance use disorder treatment models. Pharmacological Research 199, pages 106998.
Crossref
Crossref
S. B. Thal, M. Wieberneit, J. M. Sharbanee, P. M. Skeffington, R. Bruno, T. Wenge & S. J. Bright. (2023) Dosing and Therapeutic Conduct in Administration Sessions in Substance-Assisted Psychotherapy: A Systematized Review. Journal of Humanistic Psychology.
Crossref
Crossref
Adriana D’Arienzo & Giorgio Samorini. (2023) Italian psychedelic therapies of the past century: An historical overview. Drug Science, Policy and Law 9, pages 205032452311796.
Crossref
Crossref
Jay B. Nair, Linda Hakes, Berra Yazar-Klosinski & Kathryn Paisner. (2021) Fully Validated, Multi-Kilogram cGMP Synthesis of MDMA. ACS Omega 7:1, pages 900-907.
Crossref
Crossref
Wayne Hall. (2021) Why was early therapeutic research on psychedelic drugs abandoned?. Psychological Medicine 52:1, pages 26-31.
Crossref
Crossref
Matthew W. Johnson. 2022. Disruptive Psychopharmacology. Disruptive Psychopharmacology
213
227
.
Wayne Hall & Michael Farrell. (2021) What can we learn from the history of research on psychedelic drugs in the addictions?. Addiction 116:11, pages 2936-2938.
Crossref
Crossref
Sascha B. Thal, Stephen J. Bright, Jason M. Sharbanee, Tobias Wenge & Petra M. Skeffington. (2021) Current Perspective on the Therapeutic Preset for Substance-Assisted Psychotherapy. Frontiers in Psychology 12.
Crossref
Crossref
David M. O’Shaughnessy, Ilana Berlowitz, Robin Rodd, Zoltán Sarnyai & Frances Quirk. (2021) Within-treatment changes in a novel addiction treatment program using traditional Amazonian medicine. Therapeutic Advances in Psychopharmacology 11, pages 204512532098663.
Crossref
Crossref
Dominique Denis-Lalonde & Andrew Estefan. (2020) Emerging Psychedelic-Assisted Therapies: Implications for Nursing Practice. Journal of Mental Health and Addiction Nursing 4:1, pages e1-e13.
Crossref
Crossref
Aboagyewaah Oppong-Damoah, Kristen E. Curry, Bruce E. Blough, Kenner C. Rice & Kevin S. Murnane. (2019) Effects of the synthetic psychedelic 2,5-dimethoxy-4-iodoamphetamine (DOI) on ethanol consumption and place conditioning in male mice. Psychopharmacology 236:12, pages 3567-3578.
Crossref
Crossref
Albert Garcia-Romeu, Alan K Davis, Fire Erowid, Earth Erowid, Roland R Griffiths & Matthew W Johnson. (2019) Cessation and reduction in alcohol consumption and misuse after psychedelic use. Journal of Psychopharmacology 33:9, pages 1088-1101.
Crossref
Crossref
Kevin Sean Murnane, Osman F. Guner, J. Phillip Bowen, Kalyn M. Rambacher, Nader H. Moniri, Tyler J. Murphy, Cedrick Maceo Daphney, Aboagyewaah Oppong-Damoah & Kenner C. Rice. (2019) The adrenergic receptor antagonist carvedilol interacts with serotonin 2A receptors both in vitro and in vivo. Pharmacology Biochemistry and Behavior 181, pages 37-45.
Crossref
Crossref
Matthew W. Johnson, Peter S. Hendricks, Frederick S. Barrett & Roland R. Griffiths. (2019) Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacology & Therapeutics 197, pages 83-102.
Crossref
Crossref
Elizabeth M. Nielson & Jeffrey Guss. (2018) The influence of therapists’ first-hand experience with psychedelics on psychedelic-assisted psychotherapy research and therapist training. Journal of Psychedelic Studies 2:2, pages 64-73.
Crossref
Crossref
Susan Schenk & David Newcombe. (2018) Methylenedioxymethamphetamine (MDMA) in Psychiatry. Journal of Clinical Psychopharmacology 38:6, pages 632-638.
Crossref
Crossref
Steven A. Barker. (2018) N, N-Dimethyltryptamine (DMT), an Endogenous Hallucinogen: Past, Present, and Future Research to Determine Its Role and Function. Frontiers in Neuroscience 12.
Crossref
Crossref
Christian Sueur. (2018) État des lieux de la recherche sur les capacités thérapeutiques des « substances hallucinogènes » au 21 e siècle. Psychotropes Vol. 23:3, pages 125-163.
Crossref
Crossref
Katherine R. Bonson. (2017) Regulation of human research with LSD in the United States (1949-1987). Psychopharmacology 235:2, pages 591-604.
Crossref
Crossref
Erika Dyck. 2018. Plant Medicines, Healing and Psychedelic Science. Plant Medicines, Healing and Psychedelic Science
1
17
.
Robin L Carhart-Harris & Guy M Goodwin. (2017) The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future. Neuropsychopharmacology 42:11, pages 2105-2113.
Crossref
Crossref
Chris Letheby. (2017) NATURALIZING PSYCHEDELIC SPIRITUALITY. Zygon® 52:3, pages 623-642.
Crossref
Crossref
Michael P. Bogenschutz & Alyssa A. Forcehimes. (2016) Development of a Psychotherapeutic Model for Psilocybin-Assisted Treatment of Alcoholism. Journal of Humanistic Psychology 57:4, pages 389-414.
Crossref
Crossref
Celia Morgan, Amy McAndrew, Tobias Stevens, David Nutt & Will Lawn. (2017) Tripping up addiction: the use of psychedelic drugs in the treatment of problematic drug and alcohol use. Current Opinion in Behavioral Sciences 13, pages 71-76.
Crossref
Crossref
Clinton E Canal & Kevin S Murnane. (2016)
The serotonin 5-HT
2C
receptor and the non-addictive nature of classic hallucinogens
. Journal of Psychopharmacology 31:1, pages 127-143.
Crossref
Crossref
. 2016. Les addictions. Les addictions
135
142
.
Andrew R. Gallimore & Rick J. Strassman. (2016) A Model for the Application of Target-Controlled Intravenous Infusion for a Prolonged Immersive DMT Psychedelic Experience. Frontiers in Pharmacology 7.
Crossref
Crossref
Saibal Das, Preeti Barnwal, Anand Ramasamy, Sumalya Sen & Somnath Mondal. (2016) Lysergic acid diethylamide: a drug of ‘use’?. Therapeutic Advances in Psychopharmacology 6:3, pages 214-228.
Crossref
Crossref
David E. Nichols. (2016) Psychedelics. Pharmacological Reviews 68:2, pages 264-355.
Crossref
Crossref
Monica F. Tomlinson, Matthew Brown & Peter N.S. Hoaken. (2016) Recreational drug use and human aggressive behavior: A comprehensive review since 2003. Aggression and Violent Behavior 27, pages 9-29.
Crossref
Crossref
Michael P. Bogenschutz & Matthew W. Johnson. (2016) Classic hallucinogens in the treatment of addictions. Progress in Neuro-Psychopharmacology and Biological Psychiatry 64, pages 250-258.
Crossref
Crossref
L.F. Tófoli & D.B. de Araujo. 2016. Imaging the Addicted Brain. Imaging the Addicted Brain
157
185
.
Michael P. Bogenschutz & Stephen Ross. 2018. Behavioral Neurobiology of Psychedelic Drugs. Behavioral Neurobiology of Psychedelic Drugs
361
391
.
Tomislav Majić, Timo T Schmidt & Jürgen Gallinat. (2015) Peak experiences and the afterglow phenomenon: When and how do therapeutic effects of hallucinogens depend on psychedelic experiences?. Journal of Psychopharmacology 29:3, pages 241-253.
Crossref
Crossref
Michael P Bogenschutz, Alyssa A Forcehimes, Jessica A Pommy, Claire E Wilcox, PCR Barbosa & Rick J Strassman. (2015) Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. Journal of Psychopharmacology 29:3, pages 289-299.
Crossref
Crossref
Matthew W Johnson, Albert Garcia-Romeu, Mary P Cosimano & Roland R Griffiths. (2014)
Pilot study of the 5-HT
2A
R agonist psilocybin in the treatment of tobacco addiction
. Journal of Psychopharmacology 28:11, pages 983-992.
Crossref
Crossref
William A. Richards. (2014) HERE AND NOW: DISCOVERING THE SACRED WITH ENTHEOGENS. Zygon® 49:3, pages 652-665.
Crossref
Crossref
Teri S Krebs & Pål-Ørjan Johansen. (2012) Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. Journal of Psychopharmacology 26:7, pages 994-1002.
Crossref
Crossref
Michael P. Bogenschutz & Jessica M. Pommy. (2012) Therapeutic mechanisms of classic hallucinogens in the treatment of addictions: from indirect evidence to testable hypotheses. Drug Testing and Analysis 4:7-8, pages 543-555.
Crossref
Crossref
Emmanuelle A.D. Schindler, Kuldip D. Dave, Elaine M. Smolock, Vincent J. Aloyo & John A. Harvey. (2012) Serotonergic and dopaminergic distinctions in the behavioral pharmacology of (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Pharmacology Biochemistry and Behavior 101:1, pages 69-76.
Crossref
Crossref
Katherine A MacLeanMatthew W JohnsonRoland R Griffiths. (2011) Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. Journal of Psychopharmacology 25:11, pages 1453-1461.
Crossref
Crossref
Keith Fragoza & Theodore A. Alston. (2008) Liquor made quicker: alcohol as a synthetic reagent for molecules in anesthesia. Journal of Clinical Anesthesia 20:7, pages 556-559.
Crossref
Crossref
RR GriffithsWA Richards, MW Johnson, UD McCann & R. Jesse. (2008) Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. Journal of Psychopharmacology 22:6, pages 621-632.
Crossref
Crossref
MW Johnson, WA Richards & RR Griffiths. (2008) Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology 22:6, pages 603-620.
Crossref
Crossref
John C.M. Brust. 2007. Aspects neurologiques de l'addiction. Aspects neurologiques de l'addiction
385
516
.
STEPHEN J. TRAUB. 2007. Haddad and Winchester's Clinical Management of Poisoning and Drug Overdose. Haddad and Winchester's Clinical Management of Poisoning and Drug Overdose
793
802
.
Erika Dyck. (2006) ‘Hitting Highs at Rock Bottom’: LSD Treatment for Alcoholism, 1950–1970. Social History of Medicine 19:2, pages 313-329.
Crossref
Crossref
David E Nichols. (2004) Hallucinogens. Pharmacology & Therapeutics 101:2, pages 131-181.
Crossref
Crossref
John C.M. Brust. 2004. Neurological Aspects of Substance Abuse. Neurological Aspects of Substance Abuse
317
425
.
C. Ori, M. Dalsasso & U. Freo. 2004. Anaesthesia, Pain, Intensive Care and Emergency Medicine — A.P.I.C.E.. Anaesthesia, Pain, Intensive Care and Emergency Medicine — A.P.I.C.E.
863
879
.
Mary Tod Gray. (2003) Feelings of relation in the fringe of consciousness: implications for the subjective experience of addiction and the nurse-client relationship. Archives of Psychiatric Nursing 17:5, pages 237-244.
Crossref
Crossref
Michael Winkelman. (2016) Psychointegrators: Multidisciplinary Perspectives on the Therapeutic Effects of Hallucinogens. Complementary health practice review 6:3, pages 219-237.
Crossref
Crossref
Sean P Barrett, Jennifer Archambault, Marla J Engelberg & Robert O Pihl. (2000) Hallucinogenic drugs attenuate the subjective response to alcohol in humans. Human Psychopharmacology: Clinical and Experimental 15:7, pages 559-565.
Crossref
Crossref